“Big money” Positions
“Big money sentiment for Meridian Bioscience Inc (NASDAQ:VIVO) in 2018 Q2 decreased to 1.19, SEC.gov filings reveal. So its down -0.43, from 2018Q1’s 1.62. 74 investment professionals opened new or increased positions, while 62 cut down and sold their positions in Meridian Bioscience Inc so the sentiment has worsened. These funds own 36.43 million shares, that’s up from 36.20 million shares in 2018Q1. Funds holding Meridian Bioscience Inc in top 10 was flat from 0 to 0 for the same number . In total 20 funds closed positions, 42 reduced and 53 increased. Also 21 funds bought new Meridian Bioscience Inc stakes.
Significant Meridian Bioscience Inc Investors
Brown Capital Management Llc owns 3.66 million shares in Meridian Bioscience Inc as of 2018 Q2. As of 2018 Q2, 91,500 shares of Meridian Bioscience Inc are owned by Piermont Capital Management Inc.. In addition, Systematic Financial Management Lp reported 1.13 million shares in Meridian Bioscience Inc equivalent to 0.44% of its equity exposure. Connors Investor Services Inc revealed 178,983 shares position in Meridian Bioscience Inc. The North Carolina-based fund Verity Asset Management Inc. holds 27,338 shares or 0.39% of their equity exposure.
Meridian Bioscience, Inc., a life science company, develops, makes, distributes, and sells diagnostic test kits primarily for various gastrointestinal, viral, respiratory, and parasitic infectious diseases worldwide.The firm is worth $836.04 million. The firm operates through Diagnostics and Life Science divisions.The P/E ratio is 34.6. The Diagnostics segment offers testing platforms and technologies, including isothermal DNA amplification under the illumigene brand; rapid immunoassays, a single-use immunoassays that can be used in point-of-care settings under the TRU, ImmunoCard, and ImmunoCard STAT! brand names; enzyme-linked immunoassays under the Premier brand; and anodic stripping voltammetry, an electrical chemical sensor platform for quantitative determination under the LeadCare brand.
VIVO reached $19.72 during the last trading session after $0.09 change.Meridian Bioscience, Inc. is uptrending after having risen 11.66% since November 10, 2017. VIVO has 434,441 volume or 83.93% up from normal. The stock underperformed the S&P500 by 3.96%.
Mondrian Prns Ltd stated it has 0.07% in Meridian Bioscience, Inc. (NASDAQ:VIVO). Pub Sector Pension Investment Board invested in 0% or 26,771 shs. Teachers Retirement Of The State Of Kentucky has invested 0% in Meridian Bioscience, Inc. (NASDAQ:VIVO). Segall Bryant Hamill Ltd, a Illinois-based fund reported 211,886 shs. National Bank Of New York Mellon Corporation owns 811,847 shs for 0% of their capital. Federated Inc Pa accumulated 489 shs. Millennium Ltd reported 443,768 shs. Piermont Capital Mngmt holds 0.45% or 91,500 shs. Prudential Public Limited Liability Company stated it has 0.05% in Meridian Bioscience, Inc. (NASDAQ:VIVO). The New York-based Laurion Lp has invested 0% in Meridian Bioscience, Inc. (NASDAQ:VIVO). Voya Invest Mgmt Limited Liability Corp owns 18,474 shs. Credit Suisse Ag owns 142,443 shs. Georgia-based Vident Investment Advisory Lc has invested 0.02% in Meridian Bioscience, Inc. (NASDAQ:VIVO). Cwm Ltd Company accumulated 172 shs. Gsa Cap Prtnrs Llp accumulated 139,747 shs.
Meridian Bioscience, Inc. registered $31,250 net activity with 1 buying transaction and 0 sales since August 24, 2018.
For more Meridian Bioscience, Inc. (NASDAQ:VIVO) news published recently go to: Benzinga.com, Seekingalpha.com, Nasdaq.com, Nasdaq.com or Benzinga.com. The titles are as follows: “80 Biggest Movers From Yesterday” published on November 09, 2018, “Meridian Bioscience beats by $0.04, beats on revenue” on November 08, 2018, “Meridian Bioscience Reports Fourth Quarter and Full-Year Operating Results, Sets Fiscal 2019 Cash Dividend Rate …” with a publish date: November 08, 2018, “Meridian Bioscience to Hold Fourth Quarter and Full Year 2018 Financial Results Conference Call on November 8, 2018” and the last “The Daily Biotech Pulse: SITC Presentations Pick Up Pace, Sandoz’ Voluntary Recall” with publication date: November 09, 2018.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.